Source comparison
Comparison Table: Tesamorelin vs. Other GHRH Analogs
It's helpful to see where Tesamorelin fits within the broader landscape of growth hormone secretagogues. Each has a unique profile that influences its research timeline and application. Primary Mechanism GHRH Analog GHRH Analog (first 29 amino acids) GHRH Anal
This comparison does not assign a generated winner or score.
- It's helpful to see where Tesamorelin fits within the broader landscape of growth hormone secretagogues. Each has a unique profile that influences its research timeline and application.
- Primary Mechanism
- GHRH Analog
- GHRH Analog (first 29 amino acids)
- GHRH Analog with Drug Affinity Complex
- Half-Life
- ~25-40 minutes
- ~10-20 minutes
- ~6-8 days
- GH Release Pattern
- Strong, mimics natural pulse
- Milder, shorter pulse
- Sustained elevation of GH/IGF-1 levels
- Typical Onset of Action
- Weeks 2-4 (biomarkers)
- Weeks 4-8 (biomarkers)
- Days 7-14 (biomarkers)
- Time to Measurable Results
- 8-12 weeks
- 12-16 weeks
- Primary Research Focus
- Visceral Adipose Tissue (VAT) reduction
- General anti-aging, well-being
- Lean mass, sustained GH levels
- As you can see, while they all work on the GHRH receptor, their pharmacokinetic profiles are dramatically different. Tesamorelin's strength lies in its potent and specific action, leading to relatively quicker and more pronounced effects on VAT compared to something like Sermorelin. The long half-life of CJC-1295 w/ DAC creates a different hormonal environment altogether—a 'bleed' versus a 'pulse'—which is suited for different research questions. You can Find the Right Peptide Tools for Your Lab by understanding these crucial distinctions.